Aviva PLC Acquires 6,222 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aviva PLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 10.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 65,140 shares of the biopharmaceutical company's stock after purchasing an additional 6,222 shares during the quarter. Aviva PLC owned 0.06% of Regeneron Pharmaceuticals worth $46,401,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Geode Capital Management LLC boosted its holdings in Regeneron Pharmaceuticals by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock worth $1,726,940,000 after purchasing an additional 155,369 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 7.9% during the 4th quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock valued at $1,456,864,000 after buying an additional 149,124 shares during the period. Loomis Sayles & Co. L P boosted its stake in shares of Regeneron Pharmaceuticals by 33.4% in the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock worth $1,122,168,000 after buying an additional 393,997 shares during the last quarter. Amundi grew its holdings in shares of Regeneron Pharmaceuticals by 45.8% in the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after acquiring an additional 487,489 shares during the period. Finally, Norges Bank purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $802,036,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analyst Ratings Changes

REGN has been the topic of several research reports. Wells Fargo & Company dropped their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a research report on Friday, January 10th. Robert W. Baird dropped their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a report on Wednesday, February 5th. Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price for the company. TD Cowen decreased their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating on the stock in a research report on Tuesday, February 4th. Finally, UBS Group downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their price objective for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $966.88.

Regeneron Pharmaceuticals Price Performance

REGN stock traded down $0.55 during mid-day trading on Friday, hitting $545.84. The company had a trading volume of 422,505 shares, compared to its average volume of 704,306. The company has a market capitalization of $59.67 billion, a price-to-earnings ratio of 14.18, a P/E/G ratio of 2.34 and a beta of 0.44. The company has a 50-day moving average price of $662.80 and a 200 day moving average price of $758.54. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $525.99 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the business earned $11.86 earnings per share. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.